Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease.
- DOI
- 10.1186/s41687-024-00805-w
- Published
- 2024-11-13
- Container
- J Patient Rep Outcomes
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s41687-024-00805-w,
title = {Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease.},
author = {Kishnani PS and Byrne BJ and Claeys KG and Díaz-Manera J and Dimachkie MM and Kushlaf H and Mozaffar T and Roberts M and Schoser B and Hummel N and Kopiec A and Holdbrook F and Shohet S and Toscano A and PROPEL Study Group.},
year = {2024},
journal = {J Patient Rep Outcomes},
doi = {10.1186/s41687-024-00805-w},
url = {https://doi.org/10.1186/s41687-024-00805-w}
}RIS
TY - JOUR TI - Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease. AU - Kishnani PS AU - Byrne BJ AU - Claeys KG AU - Díaz-Manera J AU - Dimachkie MM AU - Kushlaf H AU - Mozaffar T AU - Roberts M AU - Schoser B AU - Hummel N AU - Kopiec A AU - Holdbrook F AU - Shohet S AU - Toscano A AU - PROPEL Study Group. PY - 2024 JO - J Patient Rep Outcomes DO - 10.1186/s41687-024-00805-w UR - https://doi.org/10.1186/s41687-024-00805-w ER -
APA
PS, K., BJ, B., KG, C., J, D., MM, D., H, K., T, M., M, R., B, S., N, H., A, K., F, H., S, S., A, T., & Group., P. S. (2024). Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease.. J Patient Rep Outcomes. https://doi.org/10.1186/s41687-024-00805-w
Source records
- europe-pmc · retrieved 2026-09-26T15:42:05.467Z
- doaj · retrieved 2026-09-26T15:42:05.476Z